- Home
- LUCD vs NKTX Comparison
LUCD vs NKTX Comparison
Compare LUCD & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | NKTX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2M | 198.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LUCD | NKTX |
|---|---|---|
| Price | $0.99 | $2.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.13 | ★ $11.33 |
| AVG Volume (30 Days) | ★ 929.3K | 488.9K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | 11.88 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,346,000.00 | N/A |
| Revenue This Year | $115.58 | N/A |
| Revenue Next Year | $130.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.90 | $1.63 |
| 52 Week High | $1.63 | $3.65 |
Technical Indicators
Market Signals| Indicator | LUCD | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 44.03 |
| Support Level | $0.90 | $2.59 |
| Resistance Level | $1.12 | $2.78 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 33.08 | 28.57 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.